Developing targeted vaccines for COVID-19 variants
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites
['FUNDING_SBIR_2'] · EMMUNE, INC · NIH-10909385
This study is testing a new type of booster vaccine designed to help people who have already been vaccinated against COVID-19 by making it better at fighting off different variants of the virus.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMMUNE, INC (nih funded) |
| Locations | 1 site (Juno Beach, UNITED STATES) |
| Trial ID | NIH-10909385 on ClinicalTrials.gov |
What this research studies
This research focuses on creating vaccine antigens specifically targeting the receptor binding domain (RBD) of the SARS-CoV-2 virus to enhance the immune response. By engineering glycosylation sites into the RBD, the researchers aim to improve the vaccine's effectiveness and reduce unwanted immune responses. The project will test these RBD-based antigens using lipid nanoparticle (LNP)-mRNA technology, comparing their ability to generate neutralizing antibodies against various COVID-19 variants. This innovative approach seeks to provide a more effective booster vaccine for individuals who have already received initial COVID-19 vaccinations.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have received initial COVID-19 vaccinations and are seeking booster options.
Not a fit: Patients who have not been vaccinated against COVID-19 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that provide stronger protection against COVID-19 variants.
How similar studies have performed: Other research has shown promise in using targeted approaches for vaccine development, indicating potential success for this novel strategy.
Where this research is happening
Juno Beach, UNITED STATES
- EMMUNE, INC — Juno Beach, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ALPERT, MICHAEL DAVID — EMMUNE, INC
- Study coordinator: ALPERT, MICHAEL DAVID
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.